1. Market Research
  2. > Alcon, Inc. – Product Pipeline Review – 2013

Alcon, Inc. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 94 pages

Alcon, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Alcon, Inc. - Product Pipeline Review - 2013” provides data on the Alcon, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Alcon, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Alcon, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Alcon, Inc. - Brief Alcon, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Alcon, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Alcon, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Alcon, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Alcon, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Alcon, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Alcon, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Alcon, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Alcon, Inc. and identify potential opportunities in those areas.

Table Of Contents

Alcon, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Alcon, Inc. Snapshot 7
Alcon, Inc. Overview 7
Key Information 7
Key Facts 7
Alcon, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Alcon, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Alcon, Inc. - Pipeline Products Glance 14
Alcon, Inc. - Late Stage Pipeline 14
Phase III Products/Combination Treatment Modalities 14
Alcon, Inc. Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Alcon, Inc. - Drug Profiles 17
(brinzolamide + brimonidine) 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
AL-39324 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
AL-53817 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
AL-54478 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
AL-60371 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
AL-78898A 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
difluprednate 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
ESBA-1008 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
secukinumab 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
tandospirone citrate 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Alcon, Inc. - Pipeline Products By Target 31
Alcon, Inc. - Pipeline Products by Route of Administration 32
Alcon, Inc. - Pipeline Products By Mechanism of Action 33
Alcon, Inc. - Recent Pipeline Updates 35
Alcon, Inc. - Dormant Projects 39
Alcon, Inc. - Discontinued Pipeline Products 40
Discontinued Pipeline Product Profiles 40
anecortave acetate 40
AL-39256 40
secukinumab 40
Alcon, Inc. - Company Statement 41
Alcon, Inc. - Locations And Subsidiaries 42
Head Office 42
Other Locations and Subsidiaries 42
Alcon, Inc. - Key Manufacturing Facilities 48
Alcon, Inc., Recent Developments 49
Alcon, Inc.- Press Release 49
Apr 19, 2013: Alcon Receives FDA Approval For Simbrinza Suspension For Glaucoma Patients 49
Oct 11, 2010: Alcon Introduces New Systane BALANCE Lubricant Eye Drops For Dry Eye Patients With Meibomian Gland Dysfunction 49
Sep 22, 2010: Alcon Launches TobraDex ST Suspension 50
Sep 22, 2010: Alcon Launches TobraDex ST Suspension In US 50
Mar 29, 2010: Alcon Completes Acquisition of Durezol from Sirion 51
Jan 18, 2010: Alcon to Purchase Ophthalmic Pharmaceutical Assets from Sirion 51
Financial Deals Landscape 53
Alcon, Inc., Deals Summary 53
Alcon, Inc., Pharmaceuticals and Healthcare, Deal Details 54
Asset Transactions 54
Alcon Acquires Ophthalmic Pharma Assets From Sirion Therapeutics 54
Partnerships 56
IRIDEX Enters Into Licensing Agreement With Alcon 56
Alcon Enters Into Licensing Agreement With Advanced Medical Optics 58
Advanced Medical Optics Enters Into Licensing Agreement With Alcon 59
Alcon Enters Into Collaboration With AstraZeneca 60
Alcon Enters Into Co-Promotion Agreement With Novartis Pharma 62
Alcon Enters Into Co-Development Agreement With Origenis 71
Licensing Agreements 72
ThromboGenics Enters Into Licensing Agreement With Alcon For Ocriplasmin 72
Alcon Enters Into Licensing Agreement With GlaxoSmithKline 74
Lantibio And TRB Chemedica Enter Into Licensing Agreement With Alcon 75
Acquisition 76
Novartis Completes Acquisition Of Remaining 23% Stake In Alcon 76
Novartis Completes Acquisition Of Additional 52% Stake In Alcon From Nestle 79
Alcon Completes Acquisition Of Optonol 83
Alcon Completes Acquisition Of EsbaTech 85
Alcon Acquires Additional 17.6% Stake In WaveLight 88
Novartis Acquires 25% Stake In Alcon From Nestle 90
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 94
Disclaimer 94



List of Tables

Alcon, Inc., Key Information 7
Alcon, Inc., Key Facts 7
Alcon, Inc. - Pipeline by Indication, 2013 10
Alcon, Inc. - Pipeline by Stage of Development, 2013 11
Alcon, Inc. - Monotherapy Products in Pipeline, 2013 12
Alcon, Inc. - Combination Treatment Modalities in Pipeline, 2013 13
Alcon, Inc. - Phase III, 2013 14
Alcon, Inc. - Phase II, 2013 15
Alcon, Inc. - Phase I, 2013 16
Alcon, Inc. - Pipeline By Target, 2013 31
Alcon, Inc. - Pipeline By Route of Administration, 2013 32
Alcon, Inc. - Pipeline Products By Mechanism of Action, 2013 34
Alcon, Inc. - Recent Pipeline Updates, 2013 35
Alcon, Inc. - Dormant Developmental Projects,2013 39
Alcon, Inc. - Discontinued Pipeline Products, 2013 40
Alcon, Inc., Other Locations 42
Alcon, Inc., Subsidiaries 47
Alcon, Inc., Key Manufacturing Facilities 48
Alcon, Inc., Deals Summary 53
Alcon Acquires Ophthalmic Pharma Assets From Sirion Therapeutics 54
IRIDEX Enters Into Licensing Agreement With Alcon 56
Alcon Enters Into Licensing Agreement With Advanced Medical Optics 58
Advanced Medical Optics Enters Into Licensing Agreement With Alcon 59
Alcon Enters Into Collaboration With AstraZeneca 60
Alcon Enters Into Co-Promotion Agreement With Novartis Pharma 62
Alcon Enters Into Co-Development Agreement With Origenis 71
ThromboGenics Enters Into Licensing Agreement With Alcon For Ocriplasmin 72
Alcon Enters Into Licensing Agreement With GlaxoSmithKline 74
Lantibio And TRB Chemedica Enter Into Licensing Agreement With Alcon 75
Novartis Completes Acquisition Of Remaining 23% Stake In Alcon 76
Novartis Completes Acquisition Of Additional 52% Stake In Alcon From Nestle 79
Alcon Completes Acquisition Of Optonol 83
Alcon Completes Acquisition Of EsbaTech 85
Alcon Acquires Additional 17.6% Stake In WaveLight 88
Novartis Acquires 25% Stake In Alcon From Nestle 90



List of Figures

Alcon, Inc. - Pipeline by Indication, 2013 9
Alcon, Inc. - Pipeline by Stage of Development, 2013 11
Alcon, Inc. - Monotherapy Products in Pipeline, 2013 12
Alcon, Inc. - Combination Treatment Modalities in Pipeline, 2013 13
Alcon, Inc. - Pipeline By Route of Administration, 2013 32
Alcon, Inc. - Pipeline Products By Mechanism of Action, 2013 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.